Entera Bio (ENTX) Retained Earnings (2017 - 2026)
Entera Bio's (ENTX) quarterly Retained Earnings came in at -$128.9 million in Q1 2026, down 10.64% YoY from -$144.3 million in Q1 2025, and down 2.82% on a QoQ basis from -$125.4 million in Q4 2025.
Entera Bio (ENTX) Retained Earnings (2017 - 2026) Analysis & Trends
Entera Bio (ENTX) has 10 years of Retained Earnings data on file, last reported at -$128.9 million in Q1 2026.
- Quarterly Retained Earnings fell 10.64% year-over-year to -$128.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$128.9 million (down 10.64% YoY) and the FY2025 annual result came in at -$125.4 million, down 10.04% from the prior year.
- Retained Earnings declined to -$128.9 million in Q1 2026, from -$125.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$86.2 million in Q1 2022 to a low of -$128.9 million in Q1 2026.
- A 5-year average of -$107.1 million and a median of -$106.4 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings sank 186.72% — and 2024, when it fell 8.53%.
- Tracing ENTX's Retained Earnings over 5 years: stood at -$95.5 million in 2022, then dropped by 9.31% to -$104.4 million in 2023, then slipped by 9.14% to -$113.9 million in 2024, then declined by 10.04% to -$125.4 million in 2025, then fell by 2.82% to -$128.9 million in 2026.
- The last three Retained Earnings figures came in at -$128.9 million (Q1 2026), -$125.4 million (Q4 2025), and -$122.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | -136.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -136.20 Mn |
| Mar 31, 2026 | -128.90 Mn |
| Dec 31, 2025 | -125.37 Mn |
| Sep 30, 2025 | -122.40 Mn |
| Jun 30, 2025 | -119.20 Mn |
| Mar 31, 2025 | -116.50 Mn |
| Dec 31, 2024 | -113.93 Mn |
| Sep 30, 2024 | -111.60 Mn |
| Jun 30, 2024 | -108.55 Mn |
| Mar 31, 2024 | -106.40 Mn |
| Dec 31, 2023 | -104.39 Mn |
| Sep 30, 2023 | -102.39 Mn |
| Jun 30, 2023 | -100.01 Mn |
| Mar 31, 2023 | -97.70 Mn |
| Dec 31, 2022 | -95.50 Mn |
| Sep 30, 2022 | -92.50 Mn |
| Jun 30, 2022 | -89.40 Mn |
| Mar 31, 2022 | -86.21 Mn |
| Dec 31, 2021 | -82.43 Mn |
| Jun 30, 2021 | 103.09 Mn |